13F-HR: Johnson & Johnson Discloses Q2 2025 Equity Holdings Valued at $334 Million

Johnson & Johnson filed its Q2 2025 Form 13F-HR, revealing a total equity portfolio value of $334.1 million across 20 distinct holdings.

Summary

• Johnson & Johnson (J&J) filed its Form 13F-HR for the calendar quarter ended June 30, 2025.
• The report details J&J's institutional investment holdings, including those managed by Johnson & Johnson Innovation JJDC, Inc.
• The total market value of the reported holdings is $334,096,397.
• The filing includes 20 distinct equity positions.
• J&J maintains sole voting authority over all reported holdings.

Sentiment

Score: 5

Explanation: The filing is a standard regulatory disclosure of investment holdings, providing factual data without inherent positive or negative sentiment regarding the filing entity's performance.

Future Outlook

NA

Industry Context

This filing provides insight into Johnson & Johnson's strategic investments, primarily through its venture capital arm, Johnson & Johnson Innovation JJDC, Inc., which focuses on healthcare, pharmaceutical, and medical technology sectors. The disclosed holdings reflect J&J's ongoing engagement with and investment in emerging and established companies within its core industry segments.

Stakeholder Impact

• Shareholders gain transparency into Johnson & Johnson's investment portfolio and strategic allocations within the healthcare and life sciences sectors.

Key Dates

Keywords

Johnson & Johnson, J&J, 13F, Holdings Report, Institutional Investment, Equity Portfolio, SEC Filing, Investment Disclosure, JJDC, Pharmaceuticals, Biotechnology, Medical Devices